High endothelial venules as potential ...
Type de document :
Article dans une revue scientifique
DOI :
URL permanente :
Titre :
High endothelial venules as potential gateways for therapeutics
Auteur(s) :
Hussain, Bilal [Auteur]
Kasinath, Vivek [Auteur]
Ashton-Rickardt, Gabriel P. [Auteur]
Clancy, Thomas [Auteur]
Uchimura, Kenji [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576
Tsokos, George [Auteur]
Abdi, Reza [Auteur]
Kasinath, Vivek [Auteur]
Ashton-Rickardt, Gabriel P. [Auteur]
Clancy, Thomas [Auteur]
Uchimura, Kenji [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576
Tsokos, George [Auteur]
Abdi, Reza [Auteur]
Titre de la revue :
Trends in Immunology
Numéro :
43
Pagination :
728-740
Éditeur :
Elsevier BV
Date de publication :
2022-08-03
ISSN :
1471-4906
Mot(s)-clé(s) en anglais :
high endothelial venule
lymph node
transplantation
cancer immunology
nanoparticles
nanomedicine
lymph node
transplantation
cancer immunology
nanoparticles
nanomedicine
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Chimie/Chimie théorique et/ou physique
Chimie/Chimie théorique et/ou physique
Résumé en anglais : [en]
High endothelial venules (HEVs) are specialized mammalian segments of vasculature that are specific to secondary lymphoid organs and hence represent potential targets for immunotherapeutics.
Antibodies that bind ...
Lire la suite >High endothelial venules (HEVs) are specialized mammalian segments of vasculature that are specific to secondary lymphoid organs and hence represent potential targets for immunotherapeutics. Antibodies that bind selectively to HEVs provide efficient targeting tools for immunotherapeutics through conjugation or encapsulation inside HEV antibody-coated nanocarriers. HEVs can also develop in organ tissues in association with autoimmune and immune-mediated disorders, including transplant rejection; they are also often found in conjunction with tertiary lymphoid organs in humans and mice. Located proximal to primary tumors, tumor-draining lymph nodes, and metastatic lesions in humans and mice, tumor-associated HEVs provide a rationale for the development of potential HEV-targeted, drug-specific delivery to cancer patients. High endothelial venules (HEVs) are specialized blood vessels that support the migration of lymphocytes from the bloodstream into lymph nodes (LNs). They are also formed ectopically in mammalian organs affected by chronic inflammation and cancer. The recent arrival of immunotherapy at the forefront of many cancer treatment regimens could boost a crucial role for HEVs as gateways for the treatment of cancer. In this review, we describe the microanatomical and biochemical characteristics of HEVs, mechanisms of formation of newly made HEVs, immunotherapies potentially dependent on HEV-mediated T cell homing to tumors, and finally, how HEV-targeted therapies might be used as a complementary approach to potentially shape the therapeutic landscape for the treatment of cancer and immune-mediated diseases.Lire moins >
Lire la suite >High endothelial venules (HEVs) are specialized mammalian segments of vasculature that are specific to secondary lymphoid organs and hence represent potential targets for immunotherapeutics. Antibodies that bind selectively to HEVs provide efficient targeting tools for immunotherapeutics through conjugation or encapsulation inside HEV antibody-coated nanocarriers. HEVs can also develop in organ tissues in association with autoimmune and immune-mediated disorders, including transplant rejection; they are also often found in conjunction with tertiary lymphoid organs in humans and mice. Located proximal to primary tumors, tumor-draining lymph nodes, and metastatic lesions in humans and mice, tumor-associated HEVs provide a rationale for the development of potential HEV-targeted, drug-specific delivery to cancer patients. High endothelial venules (HEVs) are specialized blood vessels that support the migration of lymphocytes from the bloodstream into lymph nodes (LNs). They are also formed ectopically in mammalian organs affected by chronic inflammation and cancer. The recent arrival of immunotherapy at the forefront of many cancer treatment regimens could boost a crucial role for HEVs as gateways for the treatment of cancer. In this review, we describe the microanatomical and biochemical characteristics of HEVs, mechanisms of formation of newly made HEVs, immunotherapies potentially dependent on HEV-mediated T cell homing to tumors, and finally, how HEV-targeted therapies might be used as a complementary approach to potentially shape the therapeutic landscape for the treatment of cancer and immune-mediated diseases.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CNRS
CNRS
Date de dépôt :
2022-11-18T14:05:42Z
2022-11-21T11:36:49Z
2022-11-21T11:36:49Z
Fichiers
- P22.30 HEV Potential gateways for therapeutics TrendsImmunol2022_KU.pdf
- Version finale acceptée pour publication (postprint)
- Accès libre
- Accéder au document